{"id":"https://openalex.org/W2015164232","doi":"https://doi.org/10.1158/0008-5472.can-09-3367","title":"Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan","display_name":"Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan","publication_year":2010,"publication_date":"2010-02-10","ids":{"openalex":"https://openalex.org/W2015164232","doi":"https://doi.org/10.1158/0008-5472.can-09-3367","mag":"2015164232","pmid":"https://pubmed.ncbi.nlm.nih.gov/20145144"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.can-09-3367","doi":"https://doi.org/10.1158/0008-5472.can-09-3367","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-09-3367","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038069668","display_name":"Serge A.L. Zander","orcid":"https://orcid.org/0000-0003-4756-843X","observed_orcids":["https://orcid.org/0000-0003-4756-843X"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Serge A.L. Zander","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049270608","display_name":"Ariena J. Kersbergen","orcid":"https://orcid.org/0009-0000-5306-0830","observed_orcids":["https://orcid.org/0009-0000-5306-0830"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Ariena Kersbergen","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069143905","display_name":"Eline van der Burg","orcid":"https://orcid.org/0009-0004-5748-6870","observed_orcids":["https://orcid.org/0009-0004-5748-6870"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Eline van der Burg","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049020048","display_name":"Niels de Water","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Niels de Water","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034151807","display_name":"Olaf van Tellingen","orcid":"https://orcid.org/0000-0002-1037-6269","observed_orcids":["https://orcid.org/0000-0002-1037-6269"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Olaf van Tellingen","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053487478","display_name":"Sj\u00f6fn Gunnarsdottir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Sj\u00f6fn Gunnarsdottir","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113538715","display_name":"Janneke E. Jaspers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Janneke E. Jaspers","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073106472","display_name":"Marina Pajic","orcid":"https://orcid.org/0000-0002-3871-3829","observed_orcids":["https://orcid.org/0000-0002-3871-3829"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Marina Pajic","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066160219","display_name":"Anders O.H. Nygren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Anders O.H. Nygren","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061340130","display_name":"Jos Jonkers","orcid":"https://orcid.org/0000-0002-9264-9792","observed_orcids":["https://orcid.org/0000-0002-9264-9792"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Jos Jonkers","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060054431","display_name":"Piet Borst","orcid":"https://orcid.org/0000-0002-2527-9541","observed_orcids":["https://orcid.org/0000-0002-2527-9541","https://orcid.org/0000-0002-5739-2178"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Piet Borst","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017173720","display_name":"Sven Rottenberg","orcid":"https://orcid.org/0000-0003-2044-9844","observed_orcids":["https://orcid.org/0000-0003-2044-9844"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Sven Rottenberg","raw_affiliation_strings":["Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Division of Molecular Biology, The Netherlands Cancer Institute; 2MRC-Holland, Amsterdam, the Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I2898336195"],"apc_list":null,"apc_paid":null,"fwci":4.1415,"has_fulltext":false,"cited_by_count":84,"citation_normalized_percentile":{"value":0.95531881,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"70","issue":"4","first_page":"1700","last_page":"1710"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.5845000147819519,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.5845000147819519,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.37619999051094055,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.015200000256299973,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brca1","display_name":"BRCA1","score":0.8080000281333923},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.9190000295639038},{"id":"https://openalex.org/keywords/topotecan","display_name":"topotecan","score":0.9150000214576721},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.9330000281333923},{"id":"https://openalex.org/keywords/basal-like-breast-cancer","display_name":"basal-like breast cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.7649999856948853},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.8830000162124634},{"id":"https://openalex.org/keywords/parp-inhibition","display_name":"PARP inhibition","score":0.8539999723434448},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8230000138282776},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.8410000205039978},{"id":"https://openalex.org/keywords/efflux-pumps","display_name":"efflux pumps","score":0.6629999876022339},{"id":"https://openalex.org/keywords/cancer-stem-cells","display_name":"cancer stem cells","score":0.6949999928474426},{"id":"https://openalex.org/keywords/genetically-engineered-mouse-models","display_name":"genetically engineered mouse models","score":0.6959999799728394},{"id":"https://openalex.org/keywords/homology-directed-repair","display_name":"homology-directed repair","score":0.7409999966621399},{"id":"https://openalex.org/keywords/drug-combination-toxicity","display_name":"drug combination toxicity","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C2781209748","wikidata":"https://www.wikidata.org/wiki/Q419953","display_name":"Topotecan","level":3,"score":0.974869966506958},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.9276126027107239},{"id":"https://openalex.org/C512196","wikidata":"https://www.wikidata.org/wiki/Q4650095","display_name":"Abcg2","level":5,"score":0.8113041520118713},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.6881805658340454},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6606820225715637},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.5183592438697815},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5075017809867859},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4385879337787628},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.4368409216403961},{"id":"https://openalex.org/C2778616834","wikidata":"https://www.wikidata.org/wiki/Q281044","display_name":"Topoisomerase inhibitor","level":4,"score":0.4359179437160492},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.42628684639930725},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36822575330734253},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.23669108748435974},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.23287037014961243},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.17610454559326172},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.1706812083721161},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.1182490885257721},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.10719850659370422},{"id":"https://openalex.org/C44312359","wikidata":"https://www.wikidata.org/wiki/Q286958","display_name":"ATP-binding cassette transporter","level":4,"score":0.10519328713417053},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07752436399459839},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000070997","descriptor_name":"ATP Binding Cassette Transporter, Subfamily G, Member 2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002277","descriptor_name":"Carcinoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002277","descriptor_name":"Carcinoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D002277","descriptor_name":"Carcinoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010793","descriptor_name":"Phthalazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010793","descriptor_name":"Phthalazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015674","descriptor_name":"Mammary Neoplasms, Animal","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015674","descriptor_name":"Mammary Neoplasms, Animal","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015674","descriptor_name":"Mammary Neoplasms, Animal","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016158","descriptor_name":"Genes, p53","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D018345","descriptor_name":"Mice, Knockout","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018435","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018528","descriptor_name":"ATP-Binding Cassette Transporters","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D019398","descriptor_name":"Genes, BRCA1","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D019772","descriptor_name":"Topotecan","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019772","descriptor_name":"Topotecan","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D020168","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B, Member 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1158/0008-5472.can-09-3367","doi":"https://doi.org/10.1158/0008-5472.can-09-3367","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-09-3367","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmid:20145144","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20145144","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/527f38e4-6468-4d1d-85cd-8bd805bc6089","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/sensitivity-and-acquired-resistance-of-brca1p53deficient-mouse-mammary-tumors-to-the-topoisomerase-i-inhibitor-topotecan(527f38e4-6468-4d1d-85cd-8bd805bc6089).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cancer research, 70(4), 1700 - 1710. American Association for Cancer Research Inc.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/2459318b-619d-4eb5-ac91-95ca09379fca","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/2459318b-619d-4eb5-ac91-95ca09379fca","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Zander, S A L, Kersbergen, A, van der Burg, E, de Water, N, van Tellingen, O, Gunnarsdottir, S, Jaspers, J E, Pajic, M, Nygren, A O H, Jonkers, J, Borst, P & Rottenberg, S 2010, 'Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan', Cancer research, vol. 70, no. 4, pp. 1700-1710. https://doi.org/10.1158/0008-5472.CAN-09-3367","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":56,"referenced_works":["https://openalex.org/W1496626589","https://openalex.org/W1523531555","https://openalex.org/W1546135534","https://openalex.org/W1844642259","https://openalex.org/W1850727413","https://openalex.org/W1966178564","https://openalex.org/W1968953597","https://openalex.org/W1969393767","https://openalex.org/W1973782958","https://openalex.org/W1975204412","https://openalex.org/W1979297684","https://openalex.org/W1985336260","https://openalex.org/W1992661182","https://openalex.org/W2008902935","https://openalex.org/W2014599726","https://openalex.org/W2016599680","https://openalex.org/W2019768326","https://openalex.org/W2022386942","https://openalex.org/W2027630134","https://openalex.org/W2030032972","https://openalex.org/W2032535564","https://openalex.org/W2039135884","https://openalex.org/W2041594739","https://openalex.org/W2050389304","https://openalex.org/W2051808614","https://openalex.org/W2052861371","https://openalex.org/W2055757796","https://openalex.org/W2062069198","https://openalex.org/W2079785947","https://openalex.org/W2079861630","https://openalex.org/W2082318061","https://openalex.org/W2085901921","https://openalex.org/W2111917930","https://openalex.org/W2114800396","https://openalex.org/W2118207487","https://openalex.org/W2118667947","https://openalex.org/W2119727971","https://openalex.org/W2126350892","https://openalex.org/W2131063370","https://openalex.org/W2139883287","https://openalex.org/W2144134201","https://openalex.org/W2146274229","https://openalex.org/W2148001590","https://openalex.org/W2152326762","https://openalex.org/W2154035281","https://openalex.org/W2162453996","https://openalex.org/W2166082449","https://openalex.org/W2169341639","https://openalex.org/W2171972386","https://openalex.org/W2400411938","https://openalex.org/W4256127173","https://openalex.org/W6639049465","https://openalex.org/W6645141571","https://openalex.org/W6678502805","https://openalex.org/W6681326699","https://openalex.org/W6682451367"],"related_works":["https://openalex.org/W7098032657","https://openalex.org/W7099596874","https://openalex.org/W2125708968","https://openalex.org/W2986675399","https://openalex.org/W2110634332","https://openalex.org/W2604825924","https://openalex.org/W2015360671","https://openalex.org/W1979297684","https://openalex.org/W801856368","https://openalex.org/W1982297180"],"abstract_inverted_index":{"There":[0],"is":[1,14],"no":[2],"tailored":[3],"therapy":[4],"yet":[5],"for":[6,54,145],"human":[7],"basal-like":[8],"mammary":[9],"carcinomas.":[10],"However,":[11],"BRCA1":[12],"dysfunction":[13],"frequently":[15],"present":[16],"in":[17,48,68,101,140,148,184,195],"these":[18],"malignancies,":[19],"compromising":[20],"homology-directed":[21],"DNA":[22,39],"repair.":[23],"This":[24],"defect":[25],"may":[26],"serve":[27],"as":[28,65],"the":[29,35,59,115,139,153,164,173],"tumor's":[30],"Achilles":[31],"heel":[32],"and":[33,67,109,187],"make":[34],"tumor":[36],"hypersensitive":[37],"to":[38],"breaks.":[40],"We":[41,176],"have":[42],"evaluated":[43],"this":[44,185,191],"putative":[45,158],"synthetic":[46],"lethality":[47],"a":[49,149,157],"genetically":[50],"engineered":[51],"mouse":[52,91],"model":[53],"BRCA1-associated":[55],"breast":[56],"cancer,":[57],"using":[58],"topoisomerase":[60],"I":[61],"(Top1)":[62],"poison":[63],"topotecan":[64,81,89,146,182],"monotherapy":[66],"combination":[69,174],"with":[70],"poly(ADP-ribose)":[71],"polymerase":[72],"inhibition":[73],"by":[74,172],"olaparib.":[75],"All":[76],"20":[77],"tumors":[78,94,167],"tested":[79],"were":[80,168],"sensitive,":[82],"but":[83],"response":[84],"heterogeneity":[85],"was":[86],"substantial.":[87],"Although":[88],"increased":[90,129],"survival,":[92],"all":[93],"eventually":[95],"acquired":[96],"resistance.":[97],"As":[98],"mechanisms":[99],"of":[100,107,114,126,132,143,155,163],"vivo":[102,141],"resistance,":[103],"we":[104,188],"identified":[105],"overexpression":[106],"Abcg2/Bcrp":[108],"markedly":[110],"reduced":[111],"protein":[112],"levels":[113],"drug":[116],"target":[117],"Top1":[118],"(without":[119],"altered":[120],"mRNA":[121],"levels).":[122],"Tumor-specific":[123],"genetic":[124],"ablation":[125],"Abcg2":[127],"significantly":[128],"overall":[130],"survival":[131],"topotecan-treated":[133],"animals":[134],"(P":[135],"<":[136],"0.001),":[137],"confirming":[138],"relevance":[142],"ABCG2":[144],"resistance":[147],"novel":[150],"approach.":[151],"Despite":[152],"lack":[154],"ABCG2,":[156],"tumor-initiating":[159],"cell":[160],"marker,":[161],"none":[162],"11":[165],"Abcg2(-/-);Brca1(-/-);p53(-/-)":[166],"eradicated,":[169],"not":[170],"even":[171],"topotecan-olaparib.":[175],"find":[177],"that":[178,190],"olaparib":[179],"substantially":[180],"increases":[181],"toxicity":[183],"model,":[186],"suggest":[189],"might":[192],"also":[193],"happen":[194],"humans.":[196]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":6},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":18}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}